In Brief GRAIL announces retirement of CEO Bob Ragusa, appoints President Josh Ofman as successor March 13, 2026Vol.52 No.10
Podcast One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome March 11, 2026
News Analysis GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”Mainstream epidemiologists beg to differ March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Conversation with The Cancer Letter NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
Clinical Roundup NHS-Galleri MCD trial fails to meet primary endpoint of stage shift February 27, 2026Vol.52 No.08By Sara Willa Ernst
Cancer Policy Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test February 13, 2026Vol.52 No.06By Jacquelyn Cobb and Sara Willa Ernst
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal October 31, 2025Vol.51 No.40By Jacquelyn Cobb
GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation October 25, 2024Vol.50 No.40By Jacquelyn Cobb
